采纳股份(301122) - 2024年8月28日投资者关系活动记录表

Financial Performance - In the first half of 2024, the company achieved operating revenue of 194.43 million CNY, a year-on-year increase of 9.78% [2] - The net profit attributable to shareholders was 33.20 million CNY, a year-on-year decrease of 35.30% [2] - The comprehensive gross profit margin for the period was 39.18%, indicating stable profitability [3] Business Segments - The medical device segment accounted for 54.87% of total revenue, generating 106.68 million CNY [2] - The animal device segment contributed 37.51% to total revenue, with earnings of 72.93 million CNY [2] - The laboratory consumables segment represented 6.09% of total revenue, totaling 11.85 million CNY [2] Market and Orders - The company reported a signed contract revenue amount of 106.13 million CNY, excluding products affected by the FDA import warning [3] - The company plans to actively expand into the European market and gradually establish domestic channels [3] Regulatory and Compliance - The company received the EU MDR certification for approximately 40 products in July 2024, enhancing its market access in Europe [4] - The FDA issued an import warning in April 2024 affecting certain products, which the company is addressing through legal channels [3] Future Development Plans - The company aims to strengthen its core technologies in the medical health sector and expand its product lines [5] - Plans include establishing a joint venture in Singapore and a project company in Cambodia to enhance production capabilities [3] - The company will focus on increasing R&D investment and improving product competitiveness to capture domestic market opportunities [4]